ANI Pharmaceuticals and Alimera Sciences announce closing date of merger

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their transaction pursuant to the Companies’ previously announced merger agreement before the market open on Monday, September 16, 2024.

About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company that serves patients in need by developing, manufacturing and commercializing high-quality branded and generic prescription products, including for diseases with high unmet medical needs. ANI is focused on sustainable growth by expanding its rare disease business through its flagship product, Purified Cortrophin Gel, strengthening its generics business through enhanced research and development capabilities, delivering innovation to established brands and leveraging its U.S. manufacturing footprint.